Healthcare
Euroapi S.A.(EAPIF)
Live Price
Offline$1.51
+0.00% today
1Y Change
-51.29%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $150.00M
- Revenue Growth
- -7.8%
- EPS Growth
- -61.6%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Euroapi S.A. (EAPIF) is a Healthcare stock with a market cap of $150.00M and listed on OTC. The stock last traded around $1.51 and down 51.3% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -7.8%, EPS growth of -61.6%, a dividend yield of 0.0%. What stands out right now is revenue -7.8%, EPS -61.6%, free cash flow +215.3% with operating margin -4.2% and ROIC -3.4%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EAPIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-7.8% vs +7.6% peer median
Operating Margin
Below sector median
-4.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 3, 2026 with revenue below estimates by -5.0%.
The operating picture looks softer than before
Revenue is at -7.8% and EPS is at -61.6%, with operating margin around -4.2%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 28, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -15.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 3, 2026 | โ | -27.8% | -46.4% | -46.4% |
2025 Jul 29, 2025 | โ | +0.0% | +0.0% | -15.4% |
2025 Mar 3, 2025 | โ | +0.0% | +0.0% | +17.7% |
Benchmark Edge
EAPIF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EAPIF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EAPIF Max Drawdown
-66.05%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EAPIF and SPY.
Company Overview
Euroapi S.A.
Other OTC
Euroapi SA develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. The company was incorporated in 2021 and is based in Paris, France.
- Leadership
- David Seignolle
- IPO Date
- May 20, 2022
- Employees
- 3.2k
- Street Address
- 15 Rue Traversiere
- Mailing
- Paris, 75012
- Region
- Paris, FR
- Reporting Currency
- USD
- Investor Line
- 33 1 89 20 62 00
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.7
- Price/Sales
- 0.2
- Price/Book
- 0.2
Growth
- Revenue
- -7.8%
- EPS
- -61.6%
- Free Cash Flow
- +215.3%
Profitability
- Gross Margin
- 16.8%
- Operating Margin
- -4.2%
- Net Margin
- -24.8%
- ROE
- -24.3%
- ROIC
- -3.4%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 2.60
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.